Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Pharmacology

• Publication date

  2011-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2011.03.048PMID 21497592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier

  2011cited by this paper
• Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier

  2010cited by this paper
• Alzheimer's disease: strategies for disease modification

  2010cited by this paper
• Matrix Metalloprotease-9 Inhibition Improves Amyloid β-Mediated Cognitive Impairment and Neurotoxicity in Mice

  2009cited by this paper
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

  2009cited by this paper
• Cognitive Deficit in Amyloid-&bgr;–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-&ggr; Activation

  2009cited by this paper
• Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo.

  2008cited by this paper
• Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.

  2008cited by this paper
• Intracellular amyloid-beta in Alzheimer's disease.

  2007cited by this paper
• Intracellular amyloid-β in Alzheimer's disease

  2007cited by this paper
• Nilvadipine prevents cognitive decline of patients with mild cognitive impairment

  2007cited by this paper
• Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning.

  2007cited by this paper
• Clearance of amyloid-β by circulating lipoprotein receptors

  2007cited by this paper
• Clearance of amyloid-beta by circulating lipoprotein receptors.

  2007cited by this paper
• Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

  2006cited by this paper
• Immunotherapy for Alzheimer's disease and other dementias.

  2005cited by this paper
• Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.

  2005cited by this paper
• Immunotherapy for Alzheimer's Disease and Other Dementias

  2005cited by this paper
• Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells.

  2005cited by this paper
• Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice.

  2004cited by this paper
• RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier

  2004cited by this paper
• Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation.

  2003cited by this paper
• Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid

  2003cited by this paper
• Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.

  2003cited by this paper
• RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

  2003cited by this paper
• Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans.

  2002cited by this paper
• The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.

  2002cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• Cerebral microvascular pathology in aging and Alzheimer's disease.

  2001cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Felodipine in Patients with Organic Solvent-Induced Chronic Toxic Encephalopathy

  2000cited by this paper
• Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide.

  2000cited by this paper
• The Blood‐Brain Barrier and Cerebrovascular Pathology in Alzheimer's Disease

  1999cited by this paper
• Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

  1999cited by this paper
• Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

  1999cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging.

  1999cited by this paper
• Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

  1998cited by this paper
• Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists.

  1997cited by this paper
• Pharmacokinetics of Lercanidipine in Animals: II. Distribution to and Elimination from Organs and Tissues After Administration of [14C]Lercanidipine to Rats and Dogs. Whole‐Body Autoradiography, Biliary Excretion and Enterohepatic Circulation and Biotransformation in Rats

  1997cited by this paper
• Clinical findings with nimodipine in dementia: test of the calcium hypothesis.

  1995cited by this paper
• Role of the β‐amyloid protein in Alzheimer's disease

  1995cited by this paper
• Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia.

  1990cited by this paper
• Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

  1990cited by this paper
• Spatial Localization Does Not Require the Presence of Local Cues

  1981cited by this paper

• Repurposing nicardipine leads to improved development in a young patient with Pitt–Hopkins syndrome

  2025cites this paper
• Lipid carrier-based intranasal delivery of calcium channel blockers for Alzheimer’s disease

  2025cites this paper
• Evolving Therapeutic Interventions for the Management and Treatment of Alzheimer's Disease.

  2024cites this paper
• Lercanidipine ameliorated doxorubicin-induced neuroinflammation and maintained the expressions of choline acetyltransferase via enhancing the levels of PI3K/AKT/HIF1-α expressions

  2024cites this paper
• Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles

  2024cites this paper
• Highly prevalent geriatric medications and their effect on β-amyloid fibril formation

  2024cites this paper
• Finding Drug Repurposing Candidates for Neurodegenerative Diseases using Zebrafish Behavioral Profiles

  2023cites this paper
• Amlodipine limits microglia activation and cognitive dysfunction in aged hypertensive mice

  2023cites this paper
• Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers’ Case-Control Study

  2023influential citation
• L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model.

  2023cites this paper
• Drug repositioning: Progress and challenges in drug discovery for various diseases

  2022cites this paper
• A Recent Appraisal of Small-Organic Molecules as Anti-Alzheimer's Agents.

  2022cites this paper
• A timeline of Ca2+/cAMP signalling: From basic research to potential therapeutics for dementia.

  2022cites this paper
• Different Age Related Neurological and Cardiac Effects of Verapamil on a Transgenic Mouse Model of Alzheimer's Disease

  2021cites this paper
• Roles of Microglial Ion Channel in Neurodegenerative Diseases

  2021cites this paper
• Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells

  2021cites this paper
• Repurposing Licensed Drugs for Use Against Alzheimer’s Disease

  2021cites this paper
• A cross-sectional examination of a family history of Alzheimer's disease and ApoE epsilon 4 on physical fitness, molecular biomarkers, and neurocognitive performance.

  2020cites this paper
• Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease.

  2020influential citation
• A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

  2020cites this paper
• A mechanistic insight of phytoestrogens used for Rheumatoid arthritis: An evidence-based review.

  2020cites this paper
• Therapeutic target identification, validation and drug discovery for traumatic brain injury

  2020cites this paper
• Repurposing the Dihydropyridine Calcium Channel Inhibitor Nicardipine as a Nav1.8 Inhibitor In Vivo for Pitt Hopkins Syndrome

  2020cites this paper
• Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study

  2020cites this paper
• Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI

  2020cites this paper
• Blood Pressure, Cognition, and Dementia

  2020cites this paper
• β2-adrenergic agonists rescue lysosome acidification and function in PSEN1 deficiency by reversing defective ER to lysosome delivery of ClC-7.

  2020cites this paper
• The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

  2020cites this paper
• An Autophagy Modifier Screen Identifies Small Molecules Capable of Reducing Autophagosome Accumulation in a Model of CLN3-Mediated Neurodegeneration

  2019cites this paper
• Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer’s Disease

  2019cites this paper
• Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease.

  2019cites this paper
• Repurposing Approved Drugs as Inhibitors of Kv7.1 and Nav1.8 to Treat Pitt Hopkins Syndrome

  2019cites this paper
• pharmacotherapeutical approaches of Alzheimer ’ s disease therapy

  2019cites this paper
• Antihypertensive agents in Alzheimer’s disease: beyond vascular protection

  2019cites this paper
• Exploratory analyses suggest less cognitive decline on nilvadipine treatment in very mild Alzheimer’s disease subjects

  2018cites this paper
• Old Drugs as New Treatments for Neurodegenerative Diseases

  2018cites this paper
• Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo

  2018cites this paper
• Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

  2018cites this paper
• Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells.

  2018cites this paper
• Nitrendipine and Dementia: Forgotten Positive Facts?

  2018influential citation
• Regulation of cerebral perfusion in Alzheimer’s disease: From seconds to months

  2018cites this paper
• The Contribution of Spleen Tyrosine Kinase to the Pathobiology of Alzheimer’s Disease

  2018influential citation
• Antihypertension drugs in prevention of cognition disorder and dementia: focus on calcium channel blockers and diuretics

  2018cites this paper
• Emerging amyloid and tau targeting treatments for Alzheimer’s disease

  2017cites this paper
• Amlodipine, an L‐type calcium channel blocker, protects against chlorpromazine‐induced neurobehavioural deficits in mice

  2017cites this paper
• Computational Discovery of Pharmacological Chaperones to Rectify Protein Misfolding Using a Novel Support Vector Machine Classifier

  2017cites this paper
• Investigating the passage of tetramethylpyrazine-loaded liposomes across blood-brain barrier models in vitro and ex vivo.

  2016cites this paper
• Neuroprotective Effect of Lercanidipine- A Novel Calcium Channel Blocker in Albino Mice.

  2015cites this paper
• Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review

  2015cites this paper
• A novel tacrine-dihydropyridine hybrid (-)SCR1693 induces tau dephosphorylation and inhibits Aβ generation in cells.

  2015cites this paper
• Azelnidipine attenuates inflammatory responses, superoxide and relevant signaling pathways induced by amyloid-beta in mouse cerebral endothelial cells

  2014cites this paper
• The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation*

  2014cites this paper
• Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives

  2014cites this paper
• Ginsenoside compound K promotes β-amyloid peptide clearance in primary astrocytes via autophagy enhancement

  2014cites this paper
• Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer’s Disease

  2014cites this paper
• Why calcium channel blockers could be an elite choice in the treatment of Alzheimer’s disease: a comprehensive review of evidences

  2014cites this paper
• Amyloid-β peptides, Alzheimer's disease and the blood-brain barrier.

  2013cites this paper
• Discovering new treatments for Alzheimer's disease by repurposing approved medications.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

  2013cites this paper
• Arctigenin Effectively Ameliorates Memory Impairment in Alzheimer's Disease Model Mice Targeting Both β-Amyloid Production and Clearance

  2013cites this paper
• Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats.

  2012cites this paper
• Identification and validation of target pathways influencing outcome after traumatic brain injury

  2012cites this paper
• Drug repositioning for Alzheimer's disease

  2012cites this paper
• Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

  2011cites this paper